Impact of hypertension on liver fibrosis in patients with metabolic dysfunction-associated fatty liver disease

BackgroundThis study aims to evaluate the association between hypertension and the risk of fibrosis in metabolic dysfunction–associated steatotic liver disease (MASLD) patients, as well as to investigate the impact of hypertension on the progression of liver fibrosis within this population.MethodsWe...

Full description

Saved in:
Bibliographic Details
Main Authors: Zhifeng Gao, Huan Deng, Bowen Qin, Liang Bai, Jiangwei Li, Jian Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-01-01
Series:Frontiers in Medicine
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2025.1539283/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832591656642150400
author Zhifeng Gao
Huan Deng
Bowen Qin
Liang Bai
Jiangwei Li
Jian Zhang
author_facet Zhifeng Gao
Huan Deng
Bowen Qin
Liang Bai
Jiangwei Li
Jian Zhang
author_sort Zhifeng Gao
collection DOAJ
description BackgroundThis study aims to evaluate the association between hypertension and the risk of fibrosis in metabolic dysfunction–associated steatotic liver disease (MASLD) patients, as well as to investigate the impact of hypertension on the progression of liver fibrosis within this population.MethodsWe utilized data from the NHANES 2017 to March 2020. Multivariate logistic regression models were employed to control for sociodemographic and metabolic factors to determine the associations between hypertension, MASLD, and fibrosis.ResultsOf the total cohort (N = 5,967) 57.92% had hypertension, 38.8% had MASLD, 25.88% had both MASLD and hypertension. Patients with MASLD were more likely to have hypertension (64.24% vs. 44.80%). There was a significant association between stage I (OR1.70, 95% CI: 1.15–2.53) and stage II hypertension (OR1.98, 95% CI: 1.38–2.85) and an increased risk of SF. After adjusting for multiple confounding factors, stage I (OR1.59, 95% CI: 1.09–2.24) and stage II hypertension (OR1.48, 95% CI: 1.06–2.06) remained significantly associated with the risk of SF. Patients with both MASLD and hypertension had higher rates of SF at 14.83% and AF at 7.47%. After adjusting for sociodemographic factors, those patients still had an 8.02-fold increased risk of SF (OR8.02, 95% CI: 4.47–14.39) and a 15.13-fold increased risk of AF (OR15.13, 95% CI: 7.09–32.3). Further adjustment for metabolic factors, those patients still had a significantly higher risk of SF (OR3.07, 95% CI: 1.83–5.14) and AF (OR4.01, 95% CI: 1.48–10.89).ConclusionMASLD and hypertension are at risk for fibrosis, and the coexistence of the two has a more significant impact on the risk of fibrosis.
format Article
id doaj-art-958ee64ee9fa4850af78c7a8d543cea1
institution Kabale University
issn 2296-858X
language English
publishDate 2025-01-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Medicine
spelling doaj-art-958ee64ee9fa4850af78c7a8d543cea12025-01-22T07:14:45ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2025-01-011210.3389/fmed.2025.15392831539283Impact of hypertension on liver fibrosis in patients with metabolic dysfunction-associated fatty liver diseaseZhifeng Gao0Huan Deng1Bowen Qin2Liang Bai3Jiangwei Li4Jian Zhang5Department of General Surgery Unit-4, The Second Affiliated Hospital of Xi’an, Jiaotong University Xi’an, Xi'an, Shaanxi, ChinaNational and Local Joint Engineering Research Center of Biodiagnosis and Biotherapy, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi'an, ChinaNational and Local Joint Engineering Research Center of Biodiagnosis and Biotherapy, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi'an, ChinaDepartment of General Surgery Unit-4, The Second Affiliated Hospital of Xi’an, Jiaotong University Xi’an, Xi'an, Shaanxi, ChinaDepartment of General Surgery Unit-4, The Second Affiliated Hospital of Xi’an, Jiaotong University Xi’an, Xi'an, Shaanxi, ChinaDepartment of General Surgery Unit-4, The Second Affiliated Hospital of Xi’an, Jiaotong University Xi’an, Xi'an, Shaanxi, ChinaBackgroundThis study aims to evaluate the association between hypertension and the risk of fibrosis in metabolic dysfunction–associated steatotic liver disease (MASLD) patients, as well as to investigate the impact of hypertension on the progression of liver fibrosis within this population.MethodsWe utilized data from the NHANES 2017 to March 2020. Multivariate logistic regression models were employed to control for sociodemographic and metabolic factors to determine the associations between hypertension, MASLD, and fibrosis.ResultsOf the total cohort (N = 5,967) 57.92% had hypertension, 38.8% had MASLD, 25.88% had both MASLD and hypertension. Patients with MASLD were more likely to have hypertension (64.24% vs. 44.80%). There was a significant association between stage I (OR1.70, 95% CI: 1.15–2.53) and stage II hypertension (OR1.98, 95% CI: 1.38–2.85) and an increased risk of SF. After adjusting for multiple confounding factors, stage I (OR1.59, 95% CI: 1.09–2.24) and stage II hypertension (OR1.48, 95% CI: 1.06–2.06) remained significantly associated with the risk of SF. Patients with both MASLD and hypertension had higher rates of SF at 14.83% and AF at 7.47%. After adjusting for sociodemographic factors, those patients still had an 8.02-fold increased risk of SF (OR8.02, 95% CI: 4.47–14.39) and a 15.13-fold increased risk of AF (OR15.13, 95% CI: 7.09–32.3). Further adjustment for metabolic factors, those patients still had a significantly higher risk of SF (OR3.07, 95% CI: 1.83–5.14) and AF (OR4.01, 95% CI: 1.48–10.89).ConclusionMASLD and hypertension are at risk for fibrosis, and the coexistence of the two has a more significant impact on the risk of fibrosis.https://www.frontiersin.org/articles/10.3389/fmed.2025.1539283/fullhypertensionmetabolic dysfunction-associated steatotic liver diseasesignificant fibrosisadvanced fibrosisassociation
spellingShingle Zhifeng Gao
Huan Deng
Bowen Qin
Liang Bai
Jiangwei Li
Jian Zhang
Impact of hypertension on liver fibrosis in patients with metabolic dysfunction-associated fatty liver disease
Frontiers in Medicine
hypertension
metabolic dysfunction-associated steatotic liver disease
significant fibrosis
advanced fibrosis
association
title Impact of hypertension on liver fibrosis in patients with metabolic dysfunction-associated fatty liver disease
title_full Impact of hypertension on liver fibrosis in patients with metabolic dysfunction-associated fatty liver disease
title_fullStr Impact of hypertension on liver fibrosis in patients with metabolic dysfunction-associated fatty liver disease
title_full_unstemmed Impact of hypertension on liver fibrosis in patients with metabolic dysfunction-associated fatty liver disease
title_short Impact of hypertension on liver fibrosis in patients with metabolic dysfunction-associated fatty liver disease
title_sort impact of hypertension on liver fibrosis in patients with metabolic dysfunction associated fatty liver disease
topic hypertension
metabolic dysfunction-associated steatotic liver disease
significant fibrosis
advanced fibrosis
association
url https://www.frontiersin.org/articles/10.3389/fmed.2025.1539283/full
work_keys_str_mv AT zhifenggao impactofhypertensiononliverfibrosisinpatientswithmetabolicdysfunctionassociatedfattyliverdisease
AT huandeng impactofhypertensiononliverfibrosisinpatientswithmetabolicdysfunctionassociatedfattyliverdisease
AT bowenqin impactofhypertensiononliverfibrosisinpatientswithmetabolicdysfunctionassociatedfattyliverdisease
AT liangbai impactofhypertensiononliverfibrosisinpatientswithmetabolicdysfunctionassociatedfattyliverdisease
AT jiangweili impactofhypertensiononliverfibrosisinpatientswithmetabolicdysfunctionassociatedfattyliverdisease
AT jianzhang impactofhypertensiononliverfibrosisinpatientswithmetabolicdysfunctionassociatedfattyliverdisease